AI Accelerates Drug Discovery, First FDA Approval Anticipated

Artificial intelligence is rapidly transforming drug discovery, reducing development timelines from years to months, with the industry eagerly awaiting the first FDA approval of an entirely AI-discovered drug.

The top 3

1. Three Companies Closest to FDA Approval: Schrödinger's collaborated drug, zasocitinib, is currently in Phase III clinical trials, while Insilico Medicine's Rentosertib, a fully AI-discovered and designed drug, is in Phase II, and Exscientia was among the first to bring an AI-designed molecule into human trials.
2. Top Three Most Funded AI Drug Discovery Firms: Isomorphic Labs leads with $2.7 billion in external financing, followed by Parabilis Medicines at $1.6 billion, and Eikon Therapeutics and Relay Therapeutics each with $1.5 billion in funding.
3. Three Leading AI Platforms for Early-Stage Discovery: Insilico Medicine's Pharma.AI platform uses generative chemistry and target identification, Recursion's Recursion OS focuses on phenotypic screening and large-scale biology, while Isomorphic Labs leverages an AlphaFold lineage for structure prediction and molecular design.

Sources

• 2026: the year AI stops being optional in drug discovery | Article - Drug Target
• medium.com
• AI in Drug Discovery 2026: What Actually Works, What Remains Hype, and Where the
• Artificial intelligence in drug discovery - what it is, where we stand and the p
• The Early Scale: Forbes reports AI slashes drug discovery timelines to months |

Open the full topic